Assessment of Early Detection Based on Liquid Biopsy in Intracranial Tumors: a Prospective Observational Study

Zhujiang Hospital1 site in 1 country358 target enrollmentNovember 1, 2022

ConditionsIntracranial Tumors

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Intracranial Tumors
Sponsor: Zhujiang Hospital
Enrollment: 358
Locations: 1
Primary Endpoint: The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors.
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

Registry

clinicaltrials.gov

Start Date

November 1, 2022

End Date

June 30, 2024

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Zhujiang Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors.

Time Frame: 12 months

Secondary Outcomes

The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors of different grades(WHO I-IV) and mutant subtypes(IDH mutant/wild type).(12 months)